首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   140篇
  免费   20篇
  国内免费   4篇
综合类   5篇
化学工业   57篇
机械仪表   1篇
轻工业   86篇
无线电   2篇
一般工业技术   4篇
自动化技术   9篇
  2025年   2篇
  2024年   3篇
  2023年   4篇
  2022年   13篇
  2021年   18篇
  2020年   4篇
  2019年   4篇
  2018年   5篇
  2017年   3篇
  2016年   6篇
  2015年   7篇
  2014年   5篇
  2013年   8篇
  2012年   8篇
  2011年   5篇
  2010年   7篇
  2009年   4篇
  2008年   8篇
  2007年   10篇
  2006年   10篇
  2005年   7篇
  2004年   1篇
  2003年   4篇
  2002年   2篇
  2001年   3篇
  2000年   1篇
  1999年   1篇
  1998年   3篇
  1997年   1篇
  1996年   1篇
  1995年   3篇
  1994年   2篇
  1990年   1篇
排序方式: 共有164条查询结果,搜索用时 0 毫秒
1.
Structural features associated with the ability of a monoclonalantibody (mAb) to discriminate between protein variants areidentified and engineered. The variants are the curaremimetictoxin from Naja nigricollis and erabutoxin a or b from Laticaudasemifasciata which differ from each other by 16 substitutionsand one insertion. The neutralizing mAb M1 recognizes with highaffinity a topographical epitope on the surface of toxin , butfails to recognize the erabutoxins although they possess mostof the residues forming the presumed epitope. Examinations ofthe toxin and erabutoxin 3-D structures and molecular dynamicssimulations reveal several differences between the variants.In particular, the region involving the ß-turn 17–24is organized differently. Analysis of the differences foundin this region suggests that the insertion (or deletion) atposition 18 of the variant amino add sequences is particularlyimportant in determining the differential cross-reactivity.To test this proposal, residue 18 was deleted in one erabutoxinusing sitedirected mutagenesis, and the biological propertiesof the resulting mutant were examined. We found that full antigenicitywas restored in the previously unrecognized variant. The implicationsof this finding are discussed.  相似文献   
2.
乙型肝炎病毒s基因变异株抗原表位的研究   总被引:1,自引:1,他引:1  
对HepG2细胞表达的HBsAg的点突变体129Ha、142Lf、145Rb、143Sg和148及野生型HBsAgb3进行了初步纯化及抗原表位的研究,发现这些突变体的颗粒密度与野生型HBsAg差异无显著意义,约为1.2;用5种HBsAga决定簇的单克隆抗体对其表位进行分析,发现129Ha、142Lf、145Rb和142Sg与这5种单抗的结合力与野生型HBsAg差异大显著意义,但148突变体的表位与野生型HBsAg明显不同,其原因还有待进一步研究。  相似文献   
3.
花生过敏由于其高致敏率和致敏严重性而引起了人们的广泛关注.Ara h 1是花生中的主要过敏原,属于Cupin超家族,通过抗原表位识别结合免疫球蛋白E引发花生过敏.本研究采用生物信息学分析花生主要过敏原Cupin超家族Ara h 1线性B细胞表位氨基酸组成,及其与Ara h 1二级、三级结构之间关系,通过质谱分析Ara ...  相似文献   
4.
弓形虫P30蛋白抗原表位的克隆表达及纯化鉴定   总被引:2,自引:0,他引:2  
目的构建表达P30蛋白抗原表位的重组质粒及工程菌,获得纯化的P30蛋白抗原表位,用于检测弓形虫特异性抗体。方法采用PCR技术,设计一对引物(P30P3、P30P4),从弓形虫基因组DNA中扩增出编码P30蛋白抗原表位的基因片段,与载体pET28a(+)连接,重组质粒转化大肠杆菌BL21(DE3),经IPTG诱导后进行SDSPAGE分析。用离子交换纯化表达的P30抗原表位,用ELISA鉴定其抗原性。结果表达的P30蛋白抗原表位以包涵体形式存在,纯化的P30蛋白抗原表位片段有较好的抗原性,可用于检测弓形虫抗体。结论已成功构建了高表达P30蛋白的工程菌,为研制弓形虫抗体检测试剂或疫苗奠定了基础。  相似文献   
5.
Knowledge about the orientation of ligands or inhibitors bound to a protein is vital for the development of new drugs. It was recently shown that solvent accessibility epitopes for protein ligands can be mapped by transferring magnetization from water molecules to the ligand to derive the ligand orientation. This is based on the fact that NMR signals of ligands arising from magnetization transferred from solvent molecules via the protein have a different sign from those arising from direct magnetization transfer from bulk water. Herein we critically evaluate the applicability of solvent accessibility mapping to derive binding orientations for ligands of two dehydrogenases (AKR1C3 and HSD17beta1) with very different binding pockets, including complexes in which the ligand is buried more deeply inside the protein. We also evaluate the possibility of using co-solvents, such as DMSO, for magnetization transfer.  相似文献   
6.
    
Myeloproliferative Neoplasms (MPNs) constitute a group of rare blood cancers that are characterized by mutations in bone marrow stem cells leading to the overproduction of erythrocytes, leukocytes, and thrombocytes. Mutations in calreticulin (CRT) genes may initiate MPNs, causing a novel variable polybasic stretch terminating in a common C-terminal sequence in the frameshifted CRT (CRTfs) proteins. Peptide antibodies to the mutated C-terminal are important reagents for research in the molecular mechanisms of MPNs and for the development of new diagnostic assays and therapies. In this study, eight peptide antibodies targeting the C-terminal of CRTfs were produced and characterised by modified enzyme-linked immunosorbent assays using resin-bound peptides. The antibodies reacted to two epitopes: CREACLQGWTE for SSI-HYB 385-01, 385-02, 385-03, 385-04, 385-07, 385-08, and 385-09 and CLQGWT for SSI-HYB 385-06. For the majority of antibodies, the residues Cys1, Trp9, and Glu11 were essential for reactivity. SSI-HYB 385-06, with the highest affinity, recognised recombinant CRTfs produced in yeast and the MARIMO cell line expressing CRTfs when examined in Western immunoblotting. Moreover, SSI-HYB 385-06 occasionally reacted to CRTfs from MPN patients when analysed by flow cytometry. The characterized antibodies may be used to understand the role of CRTfs in the pathogenesis of MPNs and to design and develop new diagnostic assays and therapeutic targets.  相似文献   
7.
    
Toll-like receptor (TLR) signaling plays a critical role in the induction and progression of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematous, experimental autoimmune encephalitis, type 1 diabetes mellitus and neurodegenerative diseases. Deciphering antigen recognition by antibodies provides insights and defines the mechanism of action into the progression of immune responses. Multiple strategies, including phage display and hybridoma technologies, have been used to enhance the affinity of antibodies for their respective epitopes. Here, we investigate the TLR4 antibody-binding epitope by computational-driven approach. We demonstrate that three important residues, i.e., Y328, N329, and K349 of TLR4 antibody binding epitope identified upon in silico mutagenesis, affect not only the interaction and binding affinity of antibody but also influence the structural integrity of TLR4. Furthermore, we predict a novel epitope at the TLR4-MD2 interface which can be targeted and explored for therapeutic antibodies and small molecules. This technique provides an in-depth insight into antibody–antigen interactions at the resolution and will be beneficial for the development of new monoclonal antibodies. Computational techniques, if coupled with experimental methods, will shorten the duration of rational design and development of antibody therapeutics.  相似文献   
8.
    
Nipah virus is one of the most harmful emerging viruses with deadly effects on both humans and animals. Because of the severe outbreaks, in 2018, the World Health Organization focused on the urgent need for the development of effective solutions against the virus. However, up to date, there is no effective vaccine against the Nipah virus in the market. In the current study, the complete proteome of the Nipah virus (nine proteins) was analyzed for the antigenicity score and the virulence role of each protein, where we came up with fusion glycoprotein (F), glycoprotein (G), protein (V), and protein (W) as the candidates for epitope prediction. Following that, the multitope vaccine was designed based on top-ranking CTL, HTL, and BCL epitopes from the selected proteins. We used suitable linkers, adjuvant, and PADRE peptides to finalize the constructed vaccine, which was analyzed for its physicochemical features, antigenicity, toxicity, allergenicity, and solubility. The designed vaccine passed these assessments through computational analysis and, as a final step, we ran a docking analysis between the designed vaccine and TLR-3 and validated the docked complex through molecular dynamics simulation, which estimated a strong binding and supported the nomination of the designed vaccine as a putative solution for Nipah virus. Here, we describe the computational approach for design and analysis of this vaccine.  相似文献   
9.
根据研究的需要构建了丙型肝炎病毒(HCV)B细胞表位评估模型,主要用于B细胞抗原表位的预测计估。本系统可以根据预测获得的表位区间提取表位氨基酸残基和对应的蛋白质二级结构并计算出表位的平均抗原指数得分(AI),可以保存、查询、分析预测的表位,用于多表位疫苗的设计。  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号